KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.

Alice P Chen, Geraldine O'Sullivan Coyne, Pamela L Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco, Zhongping Chen, Luiz Guilherme Darrigo, Marica Eoli, James R Whittle, Yoshihiro Nishida, Rosa Lamarca, Randolph de la Rosa Rodriguez, Ayo Adeyemi, Idoia Herrero, Nereida Llorente, Scott J Diede, Eva Dombi, Pierre Wolkenstein, KOMET study investigators

Lancet 405(10496) 2217-2230

PMID40473450
PMCIDPMC12285420
DOI10.1016/S0140-6736(25)00986-9
发表日期2025-06-05
入排依据:The study is a Phase 3, randomized, placebo-controlled trial of a drug in an oncology population, but its primary endpoint is objective response rate, not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) with Kaplan-Meier or HR reporting. Therefore, it does not meet the cohort's core requirement for a time-to-event efficacy endpoint.
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:瀑布图;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Currently, no worldwide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The KOMET study aimed to evaluate selumetinib (ARRY-142886, AZD6244) efficacy and safety in this population. METHODS: This ongoing multicentre, international, randomised, placebo-controlled, phase 3, parallel, double-blind trial randomly assigned adults with NF1-plexiform neurofibroma 1:1 to 28-day cycles of oral selumetinib 25 mg/m2 twice daily, or placebo with crossover to selumetinib at confirmed radiological progression or the end of cycle 12. The primary endpoint was objective response rate (confirmed partial or complete response) established by use of independent central review per Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria by cycle 16 (selumetinib vs placebo). This study (KOMET) is registered with ClinicalTrials.gov, NCT04924608 and is ongoing. FINDINGS: Overall, of 184 participants enrolled, 145 adults were randomly assigned to selumetinib (n=71) or placebo (n=74). Selumetinib led to a rapid response (median 3·7 months), with an objective response rate of 20% (n=14/71; 95% CI 11·2 to 30·9) by cycle 16 versus 5% (n=4/74; 1·5 to 13·3) with placebo (p=0·011). Participants with baseline chronic pain intensity scores of at least 3 had a greater reduction in score at cycle 12 with selumetinib versus placebo (least-squares mean [SE] -2·0 [0·30] -2·6 to -1·4, vs -1·3 [0·29] -1·8 to -0·7; p=0·070), although this did not reach significance; and a clinically meaningful improvement from baseline. Change from baseline to cycle 12 in PlexiQoL total scores between treatment groups was not significant (least-squares mean difference [SE] -0·1 [0·59]; -1·2 to 1·1). Adverse events were consistent with the known selumetinib safety profile. INTERPRETATION: In the first international, randomised, placebo-controlled trial in adults with NF1-plexiform neurofibromas, selumetinib achieved a significant objective response rate versus placebo. No new safety concerns were identified. The observations of reduction in tumour volume by cycle 16, reduction in chronic and spike pain, reduction in analgesia, and decrease in pain interference over placebo show that selumetinib is effective at treating plexiform neurofibromas in adults with NF1. FUNDING: AstraZeneca as part of an alliance between AstraZeneca and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ, USA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1:. (A) Study design and (B) study disposition (A) The first participant was enrolled in KOMET on 19 November 2021. The protocol included an interim analysis data cut-off for the KOMET study when the 100th randomised patient had the opportunity to complete C16. The primary analysis for the KOMET study was conducted when the last participant had the opportunity to complete their C16 assessment (5 August 2024). Participants were instructed to swallow study intervention capsules whole with a glass of water approximately 12 hours apart but no less than 6 hours apart, on an empty stomach. At the time of initiation of KOMET, the fasting requirement was still specified in the selumetinib label; therefore, no food or drink other than water was permitted for 2 hours before and 1 hour after dosing. From the end of cycle 24 (cycle 25, day 1), participants will not be required to continue to observe the fasting restriction. Dose modifications were permitted in the case of adverse events and dose reductions were mandatory according to the protocol for certain prohibited medications. Complete response was defined as disappearance of the target PN, confirmed by a consecutive scan 3–6 months after the first response. PR was defined as a ≥20% decrease in target PN volume compared with baseline, confirmed by a consecutive scan 3–6 months after the first response. PD was defined as a ≥20% increase in the target PN volume compared to baseline or the time of best response after documenting a PR. The appearance of new PN that was unequivocally and completely distinct and separate from the target PN and the non-target PN, or unequivocal progression (≥20% increase in volume) of an existing non-target PN, was also considered PD. (B) In part B, the DCO was 5 August 2024. *Symptoms may include, but were not limited to, pain, motor morbidity, and disfigurement. † Participants who signed the Informed Consent Form. ‡ Non-fulfilment of inclusion/exclusion criteria. § Two due to disease progression and one due to important protocol deviation. BID=twice daily. C=cycle. DCO=data cut-off. FAS=full analysis set. HIV=human immunodeficiency virus. IA=interim analysis. LPD=last participant dosed. LPLV=last participant last visit. MEK=mitogen-activated protein kinase. MRI=magnetic resonance imaging. NF1=neurofibromatosis type 1. ORR=objective response rate. PA=primary analysis. PAINS-pNF=PAin INtensity Scale for Plexiform Neurofibromas. PD=progressive disease. PN=plexiform neurofibroma. PR=partial response. R=randomisation. SAF=safety analysis set.
非 KM Figure
Figure 2Figure 2:. (A) Best response* in participants randomised to selumetinib (swimmer plot), FAS and (B) Target PN volume and best percentage change at the primary analysis DCO – waterfall plot, FAS (A) *Best objective response is the response a participant had following the start of intervention, but prior to starting any subsequent NF1-PN therapy and up to and including progression or the last evaluable MRI assessment in the absence of progression. The on-treatment MRI volumetric assessment period was from the first dose until discontinuation or data cut-off (whichever occurs first), excluding data during prolonged study intervention interruption (>28 continuous days of no study intervention). According to REiNS criteria, a sustained response is ≥6 months. (B) DCO was 5 August 2024. Waterfall: pre-planned visualisation. Table data are from post hoc analyses. Standard deviation of the mean was 11·3 for responders and 10·5 for non-responders. For responders, Q1 and Q3 were −46·5 and −28·1, respectively. For non-responders, Q1 and Q3 were −17·3 and −11·4, respectively. C16=cycle 16. DCO=data cut-off. FAS=full analysis set. max=maximum. min=minimum. MRI=magnetic resonance imaging. NF1=neurofibromatosis type 1. PN=plexiform neurofibroma. Q1=quartile 1. Q3=quartile 3. REiNS=Response Evaluation in Neurofibromatosis and Schwannomatosis.
非 KM Figure
Figure 3Figure 3:. Change from baseline in PAINS-pNF chronic target PN pain intensity score over time, pain FAS* Supplementary analysis. Descriptive analysis. Three placebo participants crossed over to selumetinib before cycle 12. *Pain FAS – participants randomised to study intervention with a baseline pain intensity score ≥3. BID=twice daily. C=cycle. FAS=full analysis set. PAINS-pNF=PAin INtensity Scale for Plexiform Neurofibromas. PN=plexiform neurofibroma.
非 KM Figure